Financial Results for the Fourth Quarter and Financial Year ended 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hindustan Bio Sciences Ltd reported audited standalone financial results for FY2026 ending March 31, 2026. Revenue from operations declined to Rs 73.71 lakhs from Rs 81.33 lakhs in the previous year, representing approximately 9.4% revenue decline. The company posted a net loss of Rs 7.89 lakhs for FY2026 compared to a net profit of Rs 10.08 lakhs in FY2025, a significant deterioration in profitability. The Board declared an unmodified audit opinion confirming clean financials. The company operates in a single segment (staffing services) and also approved the re-appointment of Mr. GBK Viswanadham as Internal Auditor for FY2026-27.
The stock shows concerning performance with revenue declining nearly 10% and the company swinging from profit to loss. Shareholders should monitor if this is a temporary setback or structural weakness, as the loss-making position may pressure the stock price near-term. The clean audit opinion and adequate internal controls provide some reassurance on financial reporting quality.